Veterinary Medicines

Spasmalgan compositum 500 mg/ml + 4 mg/ml Solution for injection for horses, cattle, pigs and dogs

Authorised
  • Metamizole sodium monohydrate
  • Hyoscine butylbromide
Download as PDF

Product identification

Medicine name:
Spasmalgan compositum 500 mg/ml + 4 mg/ml Solution for injection for horses, cattle, pigs and dogs
Spasmalgan compositum 500 mg/ml + 4 mg/ml Ενέσιμο διάλυμα για άλογα, βοοειδή, χοίρους και σκύλους
Active substance:
  • Metamizole sodium monohydrate
  • Hyoscine butylbromide
Target species:
  • Cattle
  • Dog
  • Horse
  • Pig
Route of administration:
  • Intravenous use
  • Intramuscular use

Product details

Active substance and strength:
  • Metamizole sodium monohydrate
    500.00
    milligram(s)
    /
    1.00
    millilitre(s)
  • Hyoscine butylbromide
    4.00
    milligram(s)
    /
    1.00
    millilitre(s)
Pharmaceutical form:
  • Solution for injection
Withdrawal period by route of administration:
  • Intravenous use
    • Cattle
      • Milk
        96
        hour
      • Meat and offal
        12
        day
    • Dog
    • Horse
      • Meat and offal
        12
        day
      • Milk
        no withdrawal period
  • Intramuscular use
    • Dog
    • Pig
      • Meat and offal
        15
        day
Anatomical therapeutic chemical veterinary (ATCvet) codes:
  • QA03DB04
Legal status of supply:
  • Veterinary medicinal product subject to veterinary prescription
Authorisation status:
  • Valid
Authorised in:
  • Cyprus
Available in:
  • Cyprus
Package description:
  • (ID2) 100 millilitre(s): Box (Cardboard) with 1 Bottle (Glass) with 100 millilitre(s), closed with Stopper and Cap (bromobutyl rubber`, Aluminium)
  • (ID1) 10 millilitre(s): Box (Cardboard) with 1 Bottle (Glass) with 10 millilitre(s), closed with Stopper and Cap (bromobutyl rubber`, Aluminium)

Additional information

Entitlement type:
  • Marketing Authorisation
Legal basis of product authorisation:
  • Generic application (Article 13(1) of Directive No 2001/82/EC)
Marketing authorisation holder:
  • Veyx Pharma GmbH
Marketing authorisation date:
Manufacturing sites for batch release:
  • Veyx Pharma GmbH
Responsible authority:
  • Veterinary Services, Ministry Of Agriculture, Natural Resources And Environment
Authorisation number:
  • CY00796V
Date of authorisation status change:
Reference member state:
  • Germany
Procedure number:
  • DE/V/0323/001
Concerned member states:
  • Austria
  • Bulgaria
  • Croatia
  • Cyprus
  • Czechia
  • Estonia
  • Greece
  • Hungary
  • Ireland
  • Italy
  • Latvia
  • Lithuania
  • Luxembourg
  • Malta
  • Poland
  • Portugal
  • Romania
  • Slovakia
  • Spain

Documents

Combined File of all Documents

English (PDF)
Published on: 11/02/2022
Download

Summary of Product Characteristics

This document does not exist in this language (English). You can find it in another language below.
Greek (PDF)
Published on: 15/06/2022
Download
How useful was this page?:
No votes yet
"Please do not include any personal data, such as your name or contact details. If you do, you consent to the processing of that data in accordance with EMA’s Privacy Statement concerning requests for information or access to documents. If you would like a reply from EMA, please Send a question to EMA instead."